Late FDG PET normalization after radioimmunotherapy in a patient with non-Hodgkin lymphoma

Clinical Nuclear Medicine

Volumn 34, Issue 11, 2009, Pages 777-778

  Maffione, Anna Margherita ^a   Castellucci, Paolo ^a   Stefoni, Vittorio ^a   Nanni, Cristina ^a   Tani, Monica ^a   Rubello, Domenico ^b   Ambrosini, Valentina ^a   Zinzani, Pierluigi ^a   Franchi, Roberto ^a   Fanti, Stefano ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Ospedale S Maria della Misericordia   (Italy)

Author keywords

Ibritumomab tiuxetan; Non Hodgkin lymphoma; Radioimmunotherapy; Zevalin

Indexed keywords

FLUDARABINE; FLUORODEOXYGLUCOSE F 18; IBRITUMOMAB TIUXETAN; MITOXANTRONE; RITUXIMAB; DIAGNOSTIC AGENT;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CASE REPORT; CLINICAL EVALUATION; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MINIMAL RESIDUAL DISEASE; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; RADIOIMMUNOTHERAPY; MIDDLE AGED; SCINTISCANNING;

FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOIMMUNOTHERAPY;

EID: 73449094233     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3181b81c34     Document Type: Article

References (9)

1. Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood. 2007;110:3507-3516.
2. Brepoels L, Stroobants S, De Wever W, et al. Aggressive and indolent non-Hodgkin's lymphoma: response assessment by integrated international workshop criteria. Leuk Lymphoma. 2007;48:1522-1530.
3. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571-578.
4. Emmanoulides C. Radioimmunotherapy for non-Hodgkin lymphoma: historical perspective and current status. J Clin Exp Hematop. 2007;47:43-60.
5. Witzig TE, Gordon LI Cabanillas F, et al. Randomized controlled trail of Yttrium 90 Labeled Ibritumomab, tiuxetan radioimmunotherapy vs Rituximab immunotherapy for patients with relapsed or refractory low grade follicular or transformed B cell non Hodgkin's lymphoma. J Clin Oncol. 2002;20:2453-2463.
6. Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol. 2003;21:1263-1270.
7. Morschhauser F, Illidge T, Huglo D, et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood. 2007;110:54-58.
8. Zinzani PL, Tani M, Fanti S, et al. A phase II trial of CHOP chemotherapy followed by Yttrium 90 Inbritumomab Tiuxetan for previuously untreated elderly diffuse large B cell lymphoma. In: ASH Annual Meeting; 2006. Abstract 609.
9. Joyce JM, Degirmenci B, Jacobs S, et al. FDG PET CT assessment of treatment response after yttrium-90 ibritumomab tiuxetan radioimmunotherapy. Clin Nucl Med. 2005;30:564-568.